CPhI 2022

Galenicum exhibits at CPhI 2022

galenicum_cphi2022_05_001-20221013133125.jpg

October, 2022

Visit us at CHPI worldwide 2022

This year we have the opportunity to reconnect in person without restrictions in one of the biggest international pharma events. 

Therefore, it is our pleasure to invite you to our stand to discuss possible collaborations together.


If you are around and would like to have a chat about our products and potential opportunities, you can find us in hall 4.1 (FDF), stand 41H20.

We offer a broad portfolio of FDF, covering all therapeutical areas and various types of technologies. We develop, license and supply Galenicum's dossiers worldwide, and we are already present in more than 50 countries.

We also have an experienced API team, so if you are looking for an API supplier, our strategic sourcing team will be happy to help.


It will be a pleasure to welcome you to our stand to discuss all about our business possibilities. Are you willing to meet any of our representatives at the event? Do not hesitate to contact us at commercial@galenicum.com.

 See you there!

Thanks for reaching out. We will get back to you as soon as possible.

RESTRICTED ACCESS

The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.

DABIGAMAX

DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.